Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
The addition of chemotherapy to dostarlimab had limited effect on dostarlimab PopPK, with no clinically significant covariates or clinically relevant exposure-safety or exposure-PFS relationships.
Authors
- Bhavana Pothuri (ORCID: https://orcid.org/0000-0003-4578-2061)
- Tom Krivak
- Stefan Zajic (ORCID: https://orcid.org/0000-0002-9844-9951)
- Floor J. Backes
- Trine Lembrecht Jørgensen (ORCID: https://orcid.org/0000-0002-7968-2694)
- Dominique Berton
- Yakir Segev (ORCID: https://orcid.org/0000-0002-3483-5845)
- Murad Melhem (ORCID: https://orcid.org/0000-0001-7002-7565)
- Oskar Alskär
- Angela Jain
- Ana Oaknin (ORCID: https://orcid.org/0000-0002-3592-7194)
- Mita Kuchimanchi (ORCID: https://orcid.org/0000-0003-0349-7756)
- Joseph Buscema
- Thierry André (ORCID: https://orcid.org/0000-0002-5103-7095)
- Sara Bouberhan (ORCID: https://orcid.org/0000-0002-0315-2152)
- Anthoula Koliadi
- Eva Hanze (ORCID: https://orcid.org/0009-0001-4926-1792)
- Mark S. Shahin (ORCID: https://orcid.org/0000-0003-1910-4523)
- Oleksandr Zub
- Christine Gennigens (ORCID: https://orcid.org/0000-0003-4526-6219)
- Mikalai Pishchyk
Institutions
- Gynecologic Oncology Group (US)
- Uppsala University (SE)
- Fox Chase Cancer Center (US)
- Uppsala University Hospital (SE)
- Thomas Jefferson University (US)
- Inserm (FR)
- Technion – Israel Institute of Technology (IL)
- Western Pennsylvania Hospital (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Odense University Hospital (DK)
- Abington Memorial Hospital (US)
- Sorbonne Université (FR)
- NYU Langone Health (US)
- Massachusetts General Hospital (US)
- The European Academy of Gynaecological Surgery (BE)
- Hôpital Saint-Antoine (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Carmel Medical Center (IL)
- GlaxoSmithKline (United States) (US)
- Vall d'Hebron Hospital Universitari (ES)
- Grodno State Medical University (BY)
- Centre Hospitalier Universitaire de Liège (BE)
- Centre de Recherche Saint-Antoine (FR)
- Chernihiv Polytechnic National University (UA)
- Jefferson Hospital (US)
- TE Laboratories (Ireland) (IE)
- Arizona Oncology (US)
- Vall d'Hebron Institute of Oncology (ES)
- The Ohio State University (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1111/bcp.16325
- Citations
- 2
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Clovis Oncology
- Myriad Genetics
- Seagen
- Eisai
- PharmaMar
- Ipsen
- EMD Serono
- Daiichi Sankyo Europe